货号:GS40332
Imgatuzumab (development code GA-201) is an investigational, humanized and glycoengineered monoclonal IgG1 antibody developed for the treatment of solid tumors, particularly those overexpressing the epidermal growth factor receptor (EGFR). It represents a next-generation anti-EGFR therapy with enhanced immune-activating properties. Its key innovation is glycoengineering: the antibody is produced in cell lines that yield a non-fucosylated Fc region.
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
迈思生物